Clinical Trial Update: TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating TP-38 toxin in pediatric patients with recurrent or progressive supratentorial high-grade glioma has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• High-grade Glioma

Drugs mentioned

• TP-38 toxin

Snippet

Sponsor: Pediatric Brain Tumor Consortium | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: TERMINATED